Condition: Cancer · Colorectal Cancer · Solid Tumor · Sponsor: Parabilis Medicines, Inc.
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
This description comes directly from the study's public registry record.
Clinical Trial Inquiries · (857) 259-6305 · clinicaltrials@parabilismed.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| Honor Health | Scottsdale, Arizona, United States | Recruiting |
| Arizona Cancer Center at University of Arizona | Tucson, Arizona, United States | Recruiting |
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | Recruiting |
| Stanford Cancer Institute, Stanford University | Palo Alto, California, United States | Recruiting |
| University of California San Francisco, Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Sarcoma Oncology Center | Santa Monica, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins University, Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Florida Cancer Specialists | Lake Mary, Florida, United States | Terminated |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05919264